{
    "paper_id": "PMC4487218",
    "metadata": {
        "title": "Function-Based Mutation-Resistant Synthetic Signaling\nDevice Activated by HIV-1 Proteolysis",
        "authors": [
            {
                "first": "Andreja",
                "middle": [],
                "last": "Majerle",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Rok",
                "middle": [],
                "last": "Gaber",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Mojca",
                "middle": [],
                "last": "Ben\u010dina",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Roman",
                "middle": [],
                "last": "Jerala",
                "suffix": "",
                "email": null,
                "affiliation": {}
            }
        ]
    },
    "body_text": [
        {
            "text": "We prepared the following plasmids:\nCD4(HA)-hivp-GAL4-VP16, FAS(HA)-hivp-GAL4-VP16, CD4(HA)-hivp-CFP-6xHis,\nand FAS(HA)-hivp-mCherry-2xNLS (Tables S1\u2013S4). We prepared the HIV-1 protease mutants pNL4\u20133.HSA.R\u2013.E\u2013(G48V/I54T)\n(hereafter referred to as G48V/I54T) with the G48V and I54T mutations\nwithin the HIV-1 protease sequence and pNL4\u20133.HSA.R\u2013.E\u2013(V82A)\n(hereafter referred to as V82A), in which the HIV-1 protease sequence\ncontains a mutation for V82A. The same mutations were also introduced\ninto the vector pcDNA3/GFP-PR (hereafter referred to as GFP-PR) to\nprepare the construct GFP-PR(G48V/I54T). The effector plasmid pABM2(IFN-\u03b21)\nwas prepared from the plasmid pABM2 with GAL4-binding sites and coding\nfor firefly luciferase, a kind gift from Dr. Mark S. Ptashne.",
            "cite_spans": [],
            "section": "DNA Constructs ::: Methods",
            "ref_spans": []
        },
        {
            "text": "The HEK293T cells were harvested\nfrom an actively growing culture and plated on 96-well tissue culture\nplates at 2 \u00d7 104 cells per well. After 24 h at approximately\n70% confluence, the cells were transfected with appropriate plasmid\ncombinations: a plasmid for fusion protein CD4(HA)-hivp-GAL4-VP16\nor FAS(HA)-hivp-GAL4-VP16, a plasmid coding for the (wild type or\nmutant) HIV-1 protease, reporter plasmid pABM2 (15 ng), and pHRL-TK\ncoding for the constitutive Renilla luciferase transfection\ncontrol. The cells were harvested 24 or 48 h after transfection. The\nactivities of the firefly luciferase and Renilla luciferase\nwere measured using the dual-luciferase assay.",
            "cite_spans": [],
            "section": "Luciferase\nReporter Assay ::: Methods",
            "ref_spans": []
        },
        {
            "text": "HEK293T cells (5 \u00d7 104 cells/well) were seeded in\n8-well tissue culture chambers.\nAt 30% confluency, the cells were transfected with plasmids: 40 ng\nof CD4(HA)-hivp-CFP-6xHis or FAS(HA)-hivp-mCherry-2xNLS with or without\n320 ng or 360 ng pNL4\u20133.HSA.R\u2013.E\u2013. The images\nwere acquired 2 days after transfection.",
            "cite_spans": [],
            "section": "Confocal Microscopy ::: Methods",
            "ref_spans": []
        },
        {
            "text": "The HEK293T cells\nwere harvested from an actively growing culture and plated on 96-well\ntissue culture plates at 2 \u00d7 104 cells per well. After\n24 h at approximately 70% confluence, the cells were transfected with\na plasmid CD4(HA)-hivp-GAL4-VP16 (10 ng), a plasmid coding for (wild\ntype or mutant) HIV-1 protease, and an effector plasmid pABM2(IFN-\u03b21).\nAt 48 or 72 h after transfection, we collected the culture medium\nand determined the IFN-\u03b21 level in the medium.",
            "cite_spans": [],
            "section": "Quantification of IFN-\u03b21\nLevels ::: Methods",
            "ref_spans": []
        }
    ],
    "ref_entries": {
        "FIGREF0": {
            "text": "Figure 1: Design\nof a mutation-resistant antiviral signaling device based\non HIV-1 protease activity. The transcriptional activator Gal4-VP16\nis anchored to the transmembrane protein domain (CD4 or FAS), where\nit is inactive. The activation step occurs via the HIV-1 protease,\nwhich cleaves the linker between the transcription factor and membrane\nanchor, thereby comprising the HIV-1 protease cleavage site. After\nthe irreversible proteolytic step, Gal4-VP16 is released from the\nmembrane and translocates into the nucleus, where it transcribes the\nselected genes under the control of the GAL4 operator, such as the\nreporter genes or genes that provide defense against viral infections.",
            "type": "figure"
        },
        "FIGREF1": {
            "text": "Figure 2: HIV-1\nprotease triggers the release of the membrane-bound reporter.\nIn cells without HIV-1 protease, the membrane localization of (a)\nCFP and (c) mCherry-2xNLS was observed. In the presence of HIV-1 protease,\n(b) CFP was released to the cytosol and (d) mCherry was released from\nthe membrane and translocated to the nucleus. An overlay of the image\nshowing the nucleus stained with Hoechst 33342 and mCherry is shown\non the left (d). The microscopic images are representative of five\nseparate observations. Scale bar = 10 \u03bcm. The HEK293T cells\nwere transfected with (a, b) 40 ng CD4(HA)-hivp-CFP-6xHis or (c, d)\n40 ng CD4(HA)-hivp-mCherry-2xNLS, as well as with the (b, d) HIV-1\ngenome-encoding plasmid pNL4\u20133.HSA.R\u2013.E\u2013 (320\nor 360 ng).",
            "type": "figure"
        },
        "FIGREF2": {
            "text": "Figure 3: Synthetic anti-HIV-1 signaling device\ndetects the activity of HIV-1\nprotease mutations resistant to protease inhibitors. (a, b, c) HEK293T\ncells were transfected with a reporter plasmid coding for the firefly\nluciferase, a plasmid constitutively expressing the Renilla luciferase, 10 ng of CD4(HA)-hivp-GAL4-VP16, and increasing amounts\nof pNL4\u20133.HSA.R\u2013.E\u2013 (pNL4\u20133 in the figure)\nor HIV-1 protease mutants (G48V/I54T or V82A) in the medium with or\nwithout saquinavir (SAQ) or saquinavir and ritonavir (SAQ/RTV). The\ncells were lysed 24 h after transfection, and the expression of the\nfirefly and Renilla luciferase reporter genes was\nanalyzed. (d, e, f) HEK293T cells were transfected with plasmids expressing\nthe firefly luciferase reporter and the constitutively expressed Renilla luciferase, CD4(HA)-hivp-GAL4-VP16 (10 ng) and pNL4\u20133.HSA.R\u2013.E\u2013,\nG48V/I54T, or V82A (all 120 ng) in the medium with or without the\nHIV-1 protease inhibitors atazanavir (ATZ), atazanavir and ritonavir\n(ATZ/RTV), saquinavir (SAQ), or saquinavir and ritonavir (SAQ/RTV).\nThe cells were lysed 24 h after transfection, and the activity of\nthe firefly and Renilla luciferase reporters was\nmeasured. Error bars represent the SD obtained from four experimental\nreplicates. The data are representative of two or three independent\nexperiments. The two-tailed Student\u2019s t-test\n(assuming a two-sample equal variance) was used for pairwise comparisons.\n***p < 0.005.",
            "type": "figure"
        },
        "FIGREF3": {
            "text": "Figure 4: Synthetic anti-HIV-1 signaling device triggers production of human\nIFN-\u03b21 in response to the viral protease. HEK293T cells were\ntransfected with an effector plasmid pABM2(IFN-\u03b21) coding for\nhuman IFN-\u03b21, 10 ng of CD4(HA)-hivp-GAL4-VP16, and increasing\namounts of pNL4\u20133.HSA.R\u2013.E\u2013 (WT in the figure)\nor HIV-1 protease mutants (G48V/I54T or V82A). IFN-\u03b2 concentrations\n(ng/mL \u00b1 SD) were determined through a comparison with a human\nIFN-\u03b2 standard curve. The data are representative of three independent\nexperiments with duplicate samples.",
            "type": "figure"
        }
    },
    "back_matter": [],
    "bib_entries": {
        "BIBREF0": {
            "title": "Antiretroviral treatment\nof adult HIV infection: 2008 recommendations of the International\nAIDS Society-U.S.A. panel",
            "authors": [],
            "year": 2008,
            "venue": "JAMA, J. Am. Med.\nAssoc.",
            "volume": "300",
            "issn": "",
            "pages": "555-570",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF1": {
            "title": "Specific DNA binding of GAL4, a positive\nregulatory protein of yeast",
            "authors": [],
            "year": 1985,
            "venue": "Cell",
            "volume": "40",
            "issn": "",
            "pages": "767-774",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF2": {
            "title": "The GAL4 system:\nA versatile system for the expression\nof genes",
            "authors": [],
            "year": 2008,
            "venue": "Methods Mol. Biol.",
            "volume": "420",
            "issn": "",
            "pages": "79-95",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF3": {
            "title": "Transcriptional\nactivation by herpes simplex virus type 1 VP16 in vitro and its inhibition by oligopeptides",
            "authors": [],
            "year": 1994,
            "venue": "Mol.\nCell. Biol.",
            "volume": "14",
            "issn": "",
            "pages": "3484-3493",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF4": {
            "title": "GAL4-VP16 is an unusually potent\ntranscriptional activator",
            "authors": [],
            "year": 1988,
            "venue": "Nature",
            "volume": "335",
            "issn": "",
            "pages": "563-564",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF5": {
            "title": "Human immunodeficiency\nvirus type\n1 protease cleavage site mutations associated with protease inhibitor\ncross-resistance selected by indinavir, ritonavir, and/or saquinavir",
            "authors": [],
            "year": 2001,
            "venue": "J. Virol.",
            "volume": "75",
            "issn": "",
            "pages": "589-594",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF6": {
            "title": "Novel fluorogenic substrates\nfor assaying retroviral proteases by resonance energy transfer",
            "authors": [],
            "year": 1990,
            "venue": "Science",
            "volume": "247",
            "issn": "",
            "pages": "954-958",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF7": {
            "title": "The gene encoding the T-cell surface protein T4 is\nlocated on human chromosome 12",
            "authors": [],
            "year": 1986,
            "venue": "Proc. Natl.\nAcad. Sci. U.S.A.",
            "volume": "83",
            "issn": "",
            "pages": "4399-4402",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF8": {
            "title": "The Fas signaling\npathway: More than a paradigm",
            "authors": [],
            "year": 2002,
            "venue": "Science",
            "volume": "296",
            "issn": "",
            "pages": "1635-1636",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF9": {
            "title": "Cell-based\nfluorescence assay for human immunodeficiency virus type 1 protease\nactivity",
            "authors": [],
            "year": 2001,
            "venue": "Antimicrob. Agents Chemother.",
            "volume": "45",
            "issn": "",
            "pages": "2616-2622",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF10": {
            "title": "Antiviral\nactions of interferons",
            "authors": [],
            "year": 2001,
            "venue": "Clin. Microbiol. Rev.",
            "volume": "14",
            "issn": "",
            "pages": "778-809",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF11": {
            "title": "Active human immunodeficiency\nvirus protease is required for viral infectivity",
            "authors": [],
            "year": 1988,
            "venue": "Proc. Natl. Acad. Sci. U.S.A.",
            "volume": "85",
            "issn": "",
            "pages": "4686-4690",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF12": {
            "title": "Domains, motifs,\nand scaffolds: The role of modular interactions in the evolution and\nwiring of cell signaling circuits",
            "authors": [],
            "year": 2006,
            "venue": "Annu. Rev.\nBiochem.",
            "volume": "75",
            "issn": "",
            "pages": "655-680",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF13": {
            "title": "Modular extracellular sensor architecture\nfor engineering mammalian cell-based devices",
            "authors": [],
            "year": 2014,
            "venue": "ACS Synth. Biol.",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.1021/sb400128g"
                ]
            }
        },
        "BIBREF14": {
            "title": "Peginterferon\nalfa-2a plus ribavirin\nfor chronic hepatitis C virus infection",
            "authors": [],
            "year": 2002,
            "venue": "N.\nEngl. J. Med.",
            "volume": "347",
            "issn": "",
            "pages": "975-982",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF15": {
            "title": "An assay to monitor HIV-1 protease activity for the\nidentification of novel inhibitors in T-cells",
            "authors": [],
            "year": 2010,
            "venue": "PloS one",
            "volume": "5",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF16": {
            "title": "Noninvasive high-throughput\nsingle-cell analysis of HIV protease activity using ratiometric flow\ncytometry",
            "authors": [],
            "year": 2013,
            "venue": "Sensors",
            "volume": "13",
            "issn": "",
            "pages": "16330-16346",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF17": {
            "title": "Quantitative assessment of in vivo HIV protease\nactivity using genetically engineered QD-based FRET probes",
            "authors": [],
            "year": 2014,
            "venue": "Biotechnol. Bioeng.",
            "volume": "111",
            "issn": "",
            "pages": "1082-1087",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF18": {
            "title": "Novel two-round\nphenotypic assay for protease inhibitor susceptibility testing of\nrecombinant and primary HIV-1 isolates",
            "authors": [],
            "year": 2012,
            "venue": "J. Clin.\nMicrobiol.",
            "volume": "50",
            "issn": "",
            "pages": "3909-3916",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF19": {
            "title": "Efficient construction\nof sequence-specific TAL effectors\nfor modulating mammalian transcription",
            "authors": [],
            "year": 2011,
            "venue": "Nat.\nBiotechnol.",
            "volume": "29",
            "issn": "",
            "pages": "149-153",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF20": {
            "title": "Engineering synthetic\nTAL effectors with orthogonal target sites",
            "authors": [],
            "year": 2012,
            "venue": "Nucleic Acids Res.",
            "volume": "40",
            "issn": "",
            "pages": "7584-7595",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF21": {
            "title": "New details of HCV\nNS3/4A proteinase functionality revealed by a high-throughput cleavage\nassay",
            "authors": [],
            "year": 2012,
            "venue": "PloS One",
            "volume": "7",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF22": {
            "title": "HIV-1 protease:\nMechanism and drug discovery",
            "authors": [],
            "year": 2003,
            "venue": "Org. Biomol. Chem.",
            "volume": "1",
            "issn": "",
            "pages": "5-14",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF23": {
            "title": "The substrate\nspecificity of SARS coronavirus 3C-like proteinase",
            "authors": [],
            "year": 2005,
            "venue": "Biochem. Biophys. Res. Commun.",
            "volume": "329",
            "issn": "",
            "pages": "934-940",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF24": {
            "title": "A P2 and P3 substrate specificity\ncomparison between the Murray Valley encephalitis and West Nile virus\nNS2B/NS3 protease using C-terminal agmatine dipeptides",
            "authors": [],
            "year": 2013,
            "venue": "Peptides",
            "volume": "52C",
            "issn": "",
            "pages": "49-52",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF25": {
            "title": "Engineering human\nimmunodeficiency virus 1 protease heterodimers as macromolecular inhibitors\nof viral maturation",
            "authors": [],
            "year": 1996,
            "venue": "Proc. Natl. Acad. Sci.\nU.S.A.",
            "volume": "93",
            "issn": "",
            "pages": "11477-11481",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF26": {
            "title": "Resistance of HIV type 1 to proteinase\ninhibitor Ro 31\u20138959",
            "authors": [],
            "year": 1995,
            "venue": "AIDS Res. Hum.\nRetroviruses",
            "volume": "11",
            "issn": "",
            "pages": "671-676",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF27": {
            "title": "Highly\ndrug-resistant HIV-1 clinical\nisolates are cross-resistant to many antiretroviral compounds in current\nclinical development",
            "authors": [],
            "year": 1999,
            "venue": "AIDS",
            "volume": "13",
            "issn": "",
            "pages": "661-667",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF28": {
            "title": "Ordered accumulation of mutations\nin HIV protease confers resistance to ritonavir",
            "authors": [],
            "year": 1996,
            "venue": "Nat. Med.",
            "volume": "2",
            "issn": "",
            "pages": "760-766",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF29": {
            "title": "Human immunodeficiency virus reverse\ntranscriptase and protease sequence database",
            "authors": [],
            "year": 1999,
            "venue": "Nucleic Acids Res.",
            "volume": "27",
            "issn": "",
            "pages": "348-352",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF30": {
            "title": "Structural basis\nfor coevolution of a human immunodeficiency virus type 1 nucleocapsid-p1\ncleavage site with a V82A drug-resistant mutation in viral protease",
            "authors": [],
            "year": 2004,
            "venue": "J. Virol.",
            "volume": "78",
            "issn": "",
            "pages": "12446-12454",
            "other_ids": {
                "DOI": []
            }
        }
    }
}